1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Cancer Therapeutics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Cancer Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Cancer Therapeutics Market Regional Analysis
6.2 Europe Cancer Therapeutics Market Revenue 2021-2031 (US$ Million)
6.3 Europe Cancer Therapeutics Market Forecast Analysis
7. Europe Cancer Therapeutics Market Analysis – by Therapy Type
7.1 Chemotherapy
- 7.1.1 Overview
- 7.1.2 Chemotherapy: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Targeted Therapy
- 7.2.1 Overview
- 7.2.2 Targeted Therapy: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Radiation Therapy
- 7.3.1 Overview
- 7.3.2 Radiation Therapy: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Hormone Therapy
- 7.4.1 Overview
- 7.4.2 Hormone Therapy: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Other Therapy Types
- 7.5.1 Overview
- 7.5.2 Other Therapy Types: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Europe Cancer Therapeutics Market Analysis – by Indications
8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Lung Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Colorectal Cancer
- 8.4.1 Overview
- 8.4.2 Colorectal Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Prostate Cancer
- 8.5.1 Overview
- 8.5.2 Prostate Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Stomach Cancer
- 8.6.1 Overview
- 8.6.2 Stomach Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.7 Cervical Cancer
- 8.7.1 Overview
- 8.7.2 Cervical Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.8 Liver & Intrahepatic Bile Duct Cancer
- 8.8.1 Overview
- 8.8.2 Liver & Intrahepatic Bile Duct Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.9 Thyroid Cancer
- 8.9.1 Overview
- 8.9.2 Thyroid Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.10 Other Indications
- 8.10.1 Overview
- 8.10.2 Other Indications: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Europe Cancer Therapeutics Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Channel
- 9.3.1 Overview
- 9.3.2 Online Channel: Europe Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Europe Cancer Therapeutics Market – Europe Analysis
10.1 Overview
10.2 Europe
- 10.2.1 Europe Cancer Therapeutics Market Breakdown, by Key
Country, 2025 and 2031 (%)
- 10.2.1.1 Europe Cancer Therapeutics Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 UK:
Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.1.1 UK: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.1.2 UK: Europe Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.1.3 UK: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.2 Germany:
Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.2.1 Germany: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.2.2 Germany: Europe Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.2.3 Germany: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.3 France:
Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.3.1 France: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.3.2 France: Europe Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.3.3 France: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.4 Russia:
Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.4.1 Russia: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.4.2 Russia: Europe Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.4.3 Russia: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.5 Italy:
Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.5.1 Italy: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.5.2 Italy: Europe Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.5.3 Italy: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.6 Rest of Europe:
Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.6.1 Rest of Europe: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.6.2 Rest of Europe: Europe Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.6.3 Rest of Europe: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Astellas Pharma Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Eli Lilly and Co
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Novartis AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Merck KGaA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 AstraZeneca
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Pfizer Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Hoffmann-La Roche Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Johnson & Johnson
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 AbbVie Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Bristol-Myers Squibb Co
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For Europe Cancer Therapeutics Market
